Liquidia Corporation (LQDA)

Currency in USD
36.350
+2.220(+6.50%)
Closed·
37.300+0.950(+2.61%)
·
LQDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
33.65036.930
52 wk Range
21.94093.610
Key Statistics
Prev. Close
36.35
Open
33.9
Day's Range
33.65-36.93
52 wk Range
21.94-93.61
Volume
4M
Average Volume (3m)
3.14M
1-Year Change
54.0907%
Book Value / Share
2.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LQDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
54.375
Upside
+49.59%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Liquidia Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 54.375
(+49.59% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy65.00+78.82%58.00Maintain15-10-2026
Needham
Buy58.00+59.56%72.00Maintain14-10-2026
BTIG
Buy70.00+92.57%-Upgrade14-10-2026
Wells Fargo
Hold33.00-9.22%30.00Maintain14-10-2026
Raymond James
Buy53.00+45.80%-Maintain08-10-2026

Liquidia Corporation Earnings Call Summary for Q2/2026

  • Liquidia posted Q2 2026 EPS of $0.74, missing estimates of $0.76, while revenue beat at $171.68M vs. $170.98M forecast; shares fell 4.6% to $84.
  • YUTREPIA sales surged 31% sequentially to $170.4M, capturing nearly 30% of inhaled prostacyclin market share on net revenue basis.
  • Company reported net income of $74.7M and adjusted EBITDA of $96.3M, marking fourth consecutive quarter of rising profitability.
  • Management reaffirmed guidance for over $1B in net revenue in 2027, despite planned doubling of R&D spending in H2 2026 for L606 Phase III trial.
  • Cash position strengthened to $284.2M, up $61.4M from Q1, with over 5,000 patients on therapy and 1,100+ prescribing physicians.
Last Updated: 12-08-2026, 07:08 pm
Read Full Transcript

Earnings

Latest Release
12-08-2026
EPS / Forecast
0.74 / 0.76
Revenue / Forecast
171.68M / 170.98M
EPS Revisions
Last 90 days

LQDA Income Statement

Compare LQDA to Peers and Sector

Metrics to compare
LQDA
Peers
Sector
Relationship
P/E Ratio
23.5x−0.1x−0.3x
PEG Ratio
0.13−0.030.00
Price/Book
16.7x2.3x2.6x
Price / LTM Sales
7.2x1.9x2.9x
Upside (Analyst Target)
49.6%77.0%64.0%
Fair Value Upside
Unlock14.9%7.8%Unlock

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Employees
216

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
28.34M31.66%967.09M
Other Institutional Investors
46.29M51.72%1.58B
Public Companies & Retail Investors
14.88M16.63%507.94M
Total
89.51M100.00%3.05B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.12.05%1,07,88,5863,68,214
Farallon Capital Management, L.L.C.9.35%83,65,0382,85,499

FAQ

What Is the Liquidia (LQDA) Share Price Today?

The Liquidia share price today is 36.350.

What is the current Liquidia (LQDA) share price and day range?

As of 21-10-2026, the Liquidia share price is 36.350, with a previous close of 36.350. The share price has ranged from 33.650 to 36.930 today, while the 52-week range spans from 21.940 to 93.610.

What Is the Liquidia Market Cap?

As of today, Liquidia market cap is 3.250B.

What Is the Liquidia (LQDA) Share Price Target?

The average 12-month share price target for Liquidia is 54.375, with a high estimate of 70 and a low estimate of 33. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +49.59% Upside potential.

What Is Liquidia's Earnings Per Share (TTM)?

The Liquidia EPS (TTM) is 1.58.

When Is the Next Liquidia Earnings Date?

Liquidia will release its next earnings report on 10-11-2026.

From a Technical Analysis Perspective, Is LQDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Liquidia Trade On?

Liquidia is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Liquidia?

The stock symbol for Liquidia is "LQDA."

How Many Times Has Liquidia Stock Split?

Liquidia has split 0 times.

How Many Employees Does Liquidia Have?

Liquidia has 216 employees.

What Is the LQDA After Hours Price?

LQDA's last after hours stock price is 37.300, the stock has changed by 0.950, or 2.610%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.